Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 SVd vs Vd in relapsed or refractory multiple myeloma
2016-003957-14Phase 3Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of selinexor in multiple myeloma (MM) (2 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Progression-free survival (IRC-assessed). Started Jan 2017; status: completed.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-003957-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003957-14.